Praxis Precision Medicines reported that ulixacaltamide met the primary endpoints in two pivotal Phase 3 trials for essential tremor, positioning the oral small-molecule T‑type calcium channel inhibitor for a regulatory filing. Company executives said the program will be discussed with the FDA as the firm prepares an NDA timeline targeting early 2026. The trials enrolled hundreds of patients across both studies and showed statistically significant improvements on primary motor and functional endpoints, with a favorable tolerability profile reported in the datasets. The results drove an immediate market reaction as investors repriced the company, reflecting renewed confidence in an oral therapy for a large unmet market of millions of patients with disabling tremor.